Cresco Labs (CRLBF) Total Non-Current Liabilities (2019 - 2026)
Cresco Labs (CRLBF) posted Total Non-Current Liabilities of $856.5 million for Q1 2026, up 1.4% on a QoQ basis from $844.6 million in Q4 2025, and down 2.15% year-over-year from $875.3 million in Q1 2025.
Cresco Labs (CRLBF) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Cresco Labs' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $856.5 million for Q1 2026.
- Quarterly Total Non-Current Liabilities fell 2.15% year-over-year to $856.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $856.5 million (down 2.15% YoY) and the FY2025 annual result came in at $844.6 million, down 3.23% from the prior year.
- Total Non-Current Liabilities was $856.5 million for Q1 2026 at Cresco Labs, up from $844.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $885.5 million in Q2 2025 and bottomed at $689.2 million in Q2 2022.
- A 5-year average of $784.0 million and a median of $740.1 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 64.23% — and 2025, when it fell 3.23%.
- Cresco Labs' Total Non-Current Liabilities stood at $740.1 million in 2022, then fell by 1.35% to $730.2 million in 2023, then climbed by 19.54% to $872.8 million in 2024, then fell by 3.23% to $844.6 million in 2025, then climbed by 1.4% to $856.5 million in 2026.
- Business Quant data shows CRLBF's Total Non-Current Liabilities at $856.5 million in Q1 2026, $844.6 million in Q4 2025, and $842.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Cresco Labs | 254.96 Mn | 99.57 Mn | 75.45 Mn | 856.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 856.48 Mn |
| Dec 31, 2025 | 844.62 Mn |
| Sep 30, 2025 | 842.79 Mn |
| Jun 30, 2025 | 885.52 Mn |
| Mar 31, 2025 | 875.34 Mn |
| Dec 31, 2024 | 872.84 Mn |
| Sep 30, 2024 | 859.00 Mn |
| Jun 30, 2024 | 846.66 Mn |
| Mar 31, 2024 | 730.94 Mn |
| Dec 31, 2023 | 730.16 Mn |
| Sep 30, 2023 | 712.41 Mn |
| Jun 30, 2023 | 726.61 Mn |
| Mar 31, 2023 | 710.63 Mn |
| Dec 31, 2022 | 740.14 Mn |
| Sep 30, 2022 | 714.28 Mn |
| Jun 30, 2022 | 689.20 Mn |
| Mar 31, 2022 | 690.00 Mn |
| Dec 31, 2021 | 694.33 Mn |
| Sep 30, 2021 | 648.42 Mn |
| Mar 31, 2021 | 420.14 Mn |